Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy

Summary

This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric Hypertrophy.

Timeline

Start

2014-10-06

Primary completion

2015-05-24

Completion

2015-08-24

Drugs

Indications